Core Viewpoint - OptimumBank Holdings, Inc. has successfully completed a comprehensive modernization of its capital structure, establishing a transparent and high-performance equity foundation to support future asset growth [1]. Group 1: Capital Structure Modernization - The Company has amended and restated the terms of its Series B Preferred Stock to enhance clarity, consistency, and transparency for investors [5]. - The Series B Preferred Stock was unified into a single series, eliminating historical sub-series and simplifying disclosure, which improves comparability and transparency across reporting periods [6]. - The Series B Preferred Stock does not provide dividend income or additional economic participation, and its amendment was aimed at reducing complexity and enhancing financial reporting clarity [7]. Group 2: Institutional Investment and Support - AllianceBernstein has increased its economic exposure to the Company through open-market purchases, direct investments, and conversions of common stock into preferred stock, reflecting long-term confidence in the Company [2][3]. - The conversion of 350,000 shares of common stock into preferred stock allows AllianceBernstein to maintain appropriate governance alignment while increasing its economic stake [3][4]. - The non-voting shares held by AllianceBernstein are fully exchangeable into voting common stock, providing flexibility while supporting the Company's growth [4]. Group 3: Future Growth and Strategy - The Company aims to push past its current $1.1 billion asset milestone, with a streamlined capital structure and strong institutional participation positioning it well for continued growth [10]. - The coordinated efforts between major institutional partners and the Board reflect a unified conviction in the Company's future and its commitment to long-term value creation [10].

Core Viewpoint - Roche is proposing a modernization of its capital structure, which includes the exchange of existing non-voting equity securities for participation certificates, to be approved at the Annual General Meeting on March 10, 2026 [1][3]. Group 1: Capital Structure Changes - The proposal includes reducing the nominal value of bearer shares from CHF 1.00 to CHF 0.001, with a cash repayment of CHF 0.999 per bearer share, totaling CHF 106,584,309 [2][9]. - The exchange of Genussscheine for participation certificates is in line with Roche's articles of incorporation and is driven by revised Swiss corporate law, ensuring that participation certificates will have the same economic rights as bearer shares [3][9]. Group 2: Dividend and Securities Management - After the dividend payment for the financial year 2025 and the capital structure changes, Roche will discontinue the issuance of printed dividend vouchers [4][6]. - Home custodians are encouraged to submit their printed certificates and dividend vouchers to a depository bank for conversion into intermediated securities to facilitate future dividend payments [5][6]. Group 3: Future Outlook - The participation certificates will be listed on the SIX Swiss Exchange and will maintain the same dividend entitlement and liquidation proceeds as bearer shares [3][9]. - Detailed explanations of the proposals will be provided to shareholders ahead of the 2026 AGM [3].